Study: Rifampicin is Likely to be the Safest Latent Tuberculosis Infection Treatment Option

Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials – The Lancet Infectious Diseases (free registration required)

Commentaries: What is the best regimen to treat latent tuberculosis infection? – The Lancet Infectious Diseases (free) AND Four Months of Rifampicin May Be Best Option for Latent TB – Medscape / Reuters (free registration required)

Related Commentary on Twitter

New study ⁦@McGill_TB⁩: “In patients without a contraindication, rifampicin is likely to be the safest latent tuberculosis infection treatment option.” https://t.co/rg2wmcLcqo

— Madhu Pai (@paimadhu) January 9, 2020